The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Virginia will be responsible for meeting client needs for both media and commercial analytics.
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Funding to grow the insurance and digital therapeutics vertical in India
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Subscribe To Our Newsletter & Stay Updated
